ReviewGland surgery2026
Parathyroidectomy timing for persistent hyperparathyroidism in kidney transplant candidates and recipients: from secondary to tertiary disease: a literature review.
Review in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Timing of parathyroidectomy in kidney transplant candidates: a systematic review and a proposed clinical algorithm.Frontiers in endocrinology · 2026Pooled it
- Second chances or surgical selection? Interpreting parathyroidectomy outcomes after kidney transplantation.Annals of medicine and surgery (2012) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) is a major challenge in the context of patients awaiting renal transplantation. Optimal timing of parathyroidectomy (PTX) for these patients remains controversial, particularly to prevent tertiary hyperparathyroidism (THPT) and minimize postoperative complications such as hungry bone syndrome (HBS). The aim of this study is to evaluate current evidence on optimal timing of PTX in renal transplant candidates. Methods: To review the current evidence regarding the optimal timing of PTX in patients with SHPT undergoing renal transplantation, a systematic search of PubMed/MEDLINE, Scopus, and Web of Science was performed using the following keywords: Key Content and Findings: Fifteen studies met inclusion criteria, including one systematic review, two narrative reviews, three cost-effectiveness analyses, eight retrospective studies and one randomized controlled trial. Early PTX (pre-transplant or within 12-18 months post-transplant) was associated with lower rates of persistent hyperparathyroidism (HPT), better biochemical control, reduced vascular calcifications, and decreased hospitalization rates. Delayed PTX (>18-24 months post-transplant) was linked to higher rates of THPT, bone loss, nephrocalcinosis, and reduced graft function. HBS occurred more frequently in pre-transplant PTX but was manageable with structured calcium/vitamin D replacement. Conclusions: PTX remains the most effective treatment for persistent HPT in renal transplant candidates. Current evidence supports pre-transplant PTX in severe SHPT or within 12-18 months after transplant if HPT persists. A multidisciplinary approach and early biochemical surveillance are essential for optimal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.